Remove tag patient-engagement
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Engagement channels. Virtual connections.

article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Additionally, when patients are prescribed medication, they are often unaware of the mechanism of action, potential side effects, interactions, and contraindications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. The three agreed on a confidential price, and the TLV determined whether the drug was cost effective for the eligible patient population. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

105
105
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

article thumbnail

Get Involved in Limb Loss and Limb Difference Awareness Month – We Dare You!

Putting Patients First Blog

Let them know about the new Youth Engagement Program. Make sure to tag the Amputee Coalition on Instagram, Facebook, and Twitter using the hashtags: #InspireToElevate, #LLLDAM, #LLAM #NoAmputeeAlone, #WeThrive. Get Involved The Amputee Coalition is a member of the National Health Council. appeared first on National Health Council.

article thumbnail

Biogen updates on its confirmatory Aduhelm trial

pharmaphorum

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

52